Most analysts take a very conservative approach to valuing biotech shares. This is probably justified as a candidate can fall at any, including the final, hurdle in the approval process. They tend to use overall trial/ approval process probabilities depending upon the stage a candidate is at eg PH1 success may be attributed 20% probability of attaining approval to market, PH2, 40%, Ph3 60% . They don't tend to look into the quality of results, how next trial structure compares with previous trial(s). NNZ2591 has soon very high safety profile, the various trials have shown very strong efficacy and PH3 endpoints will be smashed if PH2 results are repeated. I believe that the analysts are using overly conservative probabilities when assessing likelihood of success and subsequently the current value/ share price of NEU. I am slowly adding to my long-term holding as funds become available. I am sold on the company. DYOR. Not investment advice.
NEU Price at posting:
$13.63 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)